Immunology & Inflammation
Companies whose principal business activity is classified as “Biotech - Immunology & Inflammation”.
Scope: Disease-area basket spanning many mechanisms.
Leadership as of 2026-10-27: Lagging. Relative to SPY: 5 sessions +0.6pp, 21 sessions −3.6pp, 63 sessions −13.1pp. Participation 29%; 21 of 23 members eligible.
- 21-session excess -3.6pp
- 63-session excess -16.1pp (robust)
Economic family: Biotechnology
Member companies
- Xencor, Inc. (XNCR)
- Spyre Therapeutics, Inc. (SYRE)
- Arcutis Biotherapeutics, Inc. (ARQT)
- Roivant Sciences Ltd. (ROIV)
- TG Therapeutics, Inc. (TGTX)
- Protagonist Therapeutics, Inc. (PTGX)
- Viridian Therapeutics, Inc. (VRDN)
- Vor Biopharma Inc. (VOR)
- Zenas BioPharma, Inc. (ZBIO)
- Cullinan Therapeutics, Inc. (CGEM)
- AnaptysBio, Inc. (ANAB)
- Dianthus Therapeutics, Inc. (DNTH)
- Shattuck Labs, Inc. (STTK)
- Celldex Therapeutics, Inc. (CLDX)
- Immunovant, Inc. (IMVT)
- Vera Therapeutics, Inc. (VERA)
- Corvus Pharmaceuticals, Inc. (CRVS)
- Annexon, Inc. (ANNX)
- Nektar Therapeutics (NKTR)
- Avalo Therapeutics, Inc. (AVTX)
- First Tracks Biotherapeutics, I (TRAX)
- Jade Biosciences, Inc. (JBIO)
- Oruka Therapeutics, Inc. (ORKA)
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%